Literature DB >> 17539920

Potassium- and capsaicin-induced release of agmatine from spinal nerve terminals.

Cory J Goracke-Postle1, Aaron C Overland1, Maureen S Riedl1, Laura S Stone1, Carolyn A Fairbanks1.   

Abstract

Agmatine (decarboxylated arginine) was originally identified in the CNS as an imidazoline receptor ligand. Further studies demonstrated that agmatine antagonizes NMDA receptors and inhibits nitric oxide synthase. Intrathecally administered agmatine inhibits opioid tolerance and hyperalgesia evoked by inflammation, nerve injury, and intrathecally administered NMDA. These actions suggest an anti-glutamatergic role for agmatine in the spinal cord. We have previously reported that radiolabeled agmatine is transported into spinal synaptosomes in an energy- and temperature-dependent manner. In the present study, we demonstrate that agmatine is releasable from purified spinal nerve terminals upon depolarization. When exposed to either elevated potassium or capsaicin, tritiated agmatine (but not its precursor L-arginine or its metabolite putrescine) is released in a calcium-dependent manner. Control experiments confirmed that the observed release was specific to depolarization and not due to permeabilization of or degradation of synaptosomes. That capsaicin-evoked stimulation results in agmatine release implicates the participation of primary afferent nerve terminals. Radiolabeled agmatine also accumulates in purified spinal synaptosomal vesicles in a temperature-dependent manner, suggesting that the source of releasable agmatine may be vesicular in origin. These results support the proposal that agmatine may serve as a spinal neuromodulator involved in pain processing.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17539920     DOI: 10.1111/j.1471-4159.2007.04647.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

Review 1.  Neuropathology of suicide: recent findings and future directions.

Authors:  P-E Lutz; N Mechawar; G Turecki
Journal:  Mol Psychiatry       Date:  2017-07-11       Impact factor: 15.992

2.  Agmatine, by Improving Neuroplasticity Markers and Inducing Nrf2, Prevents Corticosterone-Induced Depressive-Like Behavior in Mice.

Authors:  Andiara E Freitas; Javier Egea; Izaskun Buendia; Vanessa Gómez-Rangel; Esther Parada; Elisa Navarro; Ana Isabel Casas; Aneta Wojnicz; José Avendaño Ortiz; Antonio Cuadrado; Ana Ruiz-Nuño; Ana Lúcia S Rodrigues; Manuela G Lopez
Journal:  Mol Neurobiol       Date:  2015-05-13       Impact factor: 5.590

3.  Coexpression of alpha 2A-adrenergic and delta-opioid receptors in substance P-containing terminals in rat dorsal horn.

Authors:  Maureen S Riedl; Stephen A Schnell; Aaron C Overland; Anne-Julie Chabot-Doré; Anna M Taylor; Alfredo Ribeiro-da-Silva; Robert P Elde; George L Wilcox; Laura S Stone
Journal:  J Comp Neurol       Date:  2009-04-01       Impact factor: 3.215

4.  Agmatine induces Nrf2 and protects against corticosterone effects in hippocampal neuronal cell line.

Authors:  Andiara E Freitas; Javier Egea; Izaskun Buendía; Elisa Navarro; Patricia Rada; Antonio Cuadrado; Ana Lúcia S Rodrigues; Manuela G López
Journal:  Mol Neurobiol       Date:  2014-08-02       Impact factor: 5.590

5.  Supraspinally-administered agmatine attenuates the development of oral fentanyl self-administration.

Authors:  Carrie L Wade; Daniel J Schuster; Kristine M Domingo; Kelley F Kitto; Carolyn A Fairbanks
Journal:  Eur J Pharmacol       Date:  2008-04-08       Impact factor: 4.432

6.  Immunoneutralization of agmatine sensitizes mice to micro-opioid receptor tolerance.

Authors:  Carrie L Wade; Lori L Eskridge; H Oanh X Nguyen; Kelley F Kitto; Laura S Stone; George Wilcox; Carolyn A Fairbanks
Journal:  J Pharmacol Exp Ther       Date:  2009-08-14       Impact factor: 4.030

Review 7.  Novel Targets for Fast Antidepressant Responses: Possible Role of Endogenous Neuromodulators.

Authors:  Anderson Camargo; Ana Lúcia S Rodrigues
Journal:  Chronic Stress (Thousand Oaks)       Date:  2019-06-26

8.  Agmatine requires GluN2B-containing NMDA receptors to inhibit the development of neuropathic pain.

Authors:  Cristina D Peterson; Kelley F Kitto; Harsha Verma; Kelsey Pflepsen; Eric Delpire; George L Wilcox; Carolyn A Fairbanks
Journal:  Mol Pain       Date:  2021 Jan-Dec       Impact factor: 3.395

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.